WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a protein kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) (Kalmanti et al., 2015), whereas dasatinib is the second-generation ABL kinase inhibitor used in the treatment of CML and acute lymphoblastic leukemia (ALL) (O'Hare et al., 2005).